Sapropterin

Drug Profile

Sapropterin

Alternative Names: 6R-BH4; 6R-tetrahydrobiopterin; BH4; Biopten; Kuvan; Phenoptin; Sapropterin dihydrochloride; SUN-0588; SUN0588r

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Asubio Pharma; Daiichi Sankyo Company
  • Developer Asubio Pharma; BioMarin Pharmaceutical; Daiichi Sankyo Company; Merck Serono
  • Class Anxiolytics; Nootropics; Pterins; Small molecules
  • Mechanism of Action Nitric oxide synthase stimulants; Phenylalanine hydroxylase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Phenylketonuria
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Phenylketonuria
  • Discontinued Coronary disorders; Hypertension; Kidney disorders; Peripheral arterial disorders; Pulmonary hypertension; Sickle cell anaemia; Vascular disorders

Most Recent Events

  • 13 Apr 2017 BioMarin Pharmaceutical has patent protection for Sapropterin in Europe
  • 13 Apr 2017 BioMarin Pharmaceutical enters into a patent challenge settlement agreement with Par Pharmaceutical for a generic version of sapropterin in USA
  • 01 Oct 2015 Sapropterin licensed to BioMarin worldwide (except Japan)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top